Developer docs
API playgroundTry for free, no card

Search company profiles

R42 Group

Full company profile

uuid0000vv9

Namestring
R42 Group
Legal namestring
R42 Group
Websiteurl
r42group.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

R42 Group is a Stanford, USA-based private venture capital firm that invents and finances deep-science ventures across AI, biotechnology, and technology from the pre-seed inventing stage through growth. It was established out of Dr. Ronjon Nag's Family Office (Founder and Managing Director), with public-facing operations beginning around 2020, and operates as an integrated three-arm platform. R42 Ventures is the investing arm, deploying capital and operator support directly into startups and as an LP in early-stage funds, with a disclosed track record of approximately 50 companies including prior exits to Motorola, BlackBerry, and Apple. The R42 Institute runs the educational layer through the R42 AI Fellows Program, R42 AI Founders Institute, R42 AI and Longevity Club, and R42 Longevity Series, intended as a talent and deal-flow pipeline into the investment arm. The R42 AI Equities Fund, launched in 2024 and co-managed with Dr. Frank Sortino, applies AI-driven predictive analytics and portfolio optimization to public-market equities as a separately managed vehicle beyond the private portfolio. Recent strategic activity includes the February 2026 strategic alliance with capAI PLC and participation in UK-based xWatts' £1.6M seed round.

R42 generates revenue through standard VC mechanics — management fees and carried interest on its direct investment vehicles, the LP commitments underlying its fund-of-funds activity, and fees on the R42 AI Equities Fund — none of which are publicly disclosed. The firm is privately held by the Nag family office, employs 1–10 people, and reports no public revenue, AUM, or fee schedule. Go-to-market is deal-by-deal through direct origination, advisor networks anchored by Stanford faculty, and the Institute's event and program pipeline; customer segments are institutional/individual LPs and portfolio founders rather than enterprise SaaS buyers.

Short descriptiontext

R42 Group is a Stanford-based private venture capital firm that invents and finances deep-science ventures in AI, biotechnology, and technology through three integrated arms: R42 Ventures (direct and LP investing), R42 Institute (AI and longevity education and community), and the R42 AI Equities Fund (AI-driven public equities).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStanford, United States
HQ citystring
Stanford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital investing, deep science ventures, AI startup financing, biotech investment, growth stage capital
Industry2 codes
1Independent Venture Debt Funds / Platforms
CodeFSANAIABPrimaryYes
2Corporate Strategic Real Assets & Infrastructure Venture Investing
CodeFSANAHANPrimaryNo
NAICS code1 code
  • Other Financial Vehicles525990
Product category
Venture Capital Services
Social media profiles3 records
Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1R42 Ventures
Description

Venture capital arm that invents and finances deep science ventures across AI, biotech, and technology from pre-seed to growth stage

r42group.com
+3 more records
Core offering1 text field

R42 Group is a venture capital firm that actively invents and finances deep science ventures across AI, biotechnology, and technology, supporting portfolio companies from pre-seed through growth stage. It operates three integrated arms: R42 Ventures (direct investment and operator support), the R42 Institute (AI and longevity education programs), and the R42 AI Equities Fund (an AI-driven public-markets equity fund).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

R42 Group operates as a single integrated deep-science platform with three interconnected arms rather than a traditional SaaS product: R42 Ventures finances deep-science startups (AI, biotechnology, technology); the R42 Institute runs the educational and community layer through the R42 AI Fellows Program, R42 AI Founders Institute, R42 AI and Longevity Club, and R42 Longevity Series; and the R42 AI Equities Fund is the firm's AI-driven public-markets investment vehicle that applies predictive analytics and portfolio optimization. Together, these modules form a "invent–invest–inform" stack in which R42 Institute and its events pipeline founders into R42 Ventures' portfolio and inform the AI Equities Fund's strategy, while strategic alliances such as the R42 × capAI PLC partnership extend the platform's AI reach into adjacent media products.

Product and service3 records
1R42 Ventures
CategoryVenture Capital Investing
2R42 AI Equities Fund
CategoryAI-Driven Investment Fund
3R42 Institute
CategoryEducation and Research
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

R42 has a strategic alliance with capAI PLC.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Deep-tech and science-focused venture capital firm investing in AI, biotech, and frontier technology. Directly comparable to R42's deep-science mandate, with a longer track record and larger fund base, serving similar founders and institutional LPs.

TypeDirect peer
Description

Venture capital firm with a strong deep-tech, AI, and biotech investment thesis across pre-seed through growth. Highly comparable to R42 Ventures' thematic scope and stage range, though at significantly larger fund scale.

TypeDirect peer
Description

Venture capital firm investing in deep-tech companies at the intersection of computation and the physical world (AI, biotech, materials). Directly comparable to R42's deep-science, AI-heavy investment focus.

TypeDirect peer
Description

Long-standing deep-science and biotech venture capital firm, investing from seed through growth in breakthrough science. Closely matches R42's biotech/longevity and deep-tech emphasis, though typically earlier at the scientific-research stage.

TypeBroad incumbent
Description

Established broad technology venture capital firm with a deep-tech, science-friendly mandate and AI/tech portfolio exposure. Less specialized in biotech/longevity than R42, but overlapping in AI and frontier-tech investing.

TypeDirect peer
Description

Venture capital firm investing at the intersection of technology and life sciences (AI, biotech, healthcare). Closely aligned with R42's dual AI/longevity focus and similar stage range from seed to growth.

TypeDirect peer
Description

Science-driven venture capital firm investing in AI, health, and sustainable technology. Compares directly to R42's thematic focus on AI and longevity, with overlapping founder and impact-oriented theses.

TypeDirect peer
Description

Venture studio and investor focused on founding deep-science companies across AI, biotech, and climate. Closely mirrors R42's "invent and finance" model of co-creating deep-science ventures from pre-seed, though with a more structured studio approach.

TypeEmerging player
Description

Talent-first investor that builds and funds deep-tech founders from the earliest stages. Comparable to R42 Institute's AI Fellows / Founders Institute as a founder-funnel mechanism feeding into R42 Ventures, though EF operates as a global program.

TypeDirect peer
Description

AI-focused venture capital firm investing in early-stage AI companies, founded by leading AI researchers. Directly comparable to R42 Ventures on the AI investment thesis, with similarly strong research/operator networks and deep-tech specialization.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment31 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

R42 Group

Venture Capital Servicesr42group.com

R42 Group is a Stanford-based private venture capital firm that invents and finances deep-science ventures in AI, biotechnology, and technology through three integrated arms: R42 Ventures (direct and LP investing), R42 Institute (AI and longevity education and community), and the R42 AI Equities Fund (AI-driven public equities).

What R42 Group does

R42 Group is a Stanford, USA-based private venture capital firm that invents and finances deep-science ventures across AI, biotechnology, and technology from the pre-seed inventing stage through growth. It was established out of Dr. Ronjon Nag's Family Office (Founder and Managing Director), with public-facing operations beginning around 2020, and operates as an integrated three-arm platform. R42 Ventures is the investing arm, deploying capital and operator support directly into startups and as an LP in early-stage funds, with a disclosed track record of approximately 50 companies including prior exits to Motorola, BlackBerry, and Apple. The R42 Institute runs the educational layer through the R42 AI Fellows Program, R42 AI Founders Institute, R42 AI and Longevity Club, and R42 Longevity Series, intended as a talent and deal-flow pipeline into the investment arm. The R42 AI Equities Fund, launched in 2024 and co-managed with Dr. Frank Sortino, applies AI-driven predictive analytics and portfolio optimization to public-market equities as a separately managed vehicle beyond the private portfolio. Recent strategic activity includes the February 2026 strategic alliance with capAI PLC and participation in UK-based xWatts' £1.6M seed round.

R42 generates revenue through standard VC mechanics — management fees and carried interest on its direct investment vehicles, the LP commitments underlying its fund-of-funds activity, and fees on the R42 AI Equities Fund — none of which are publicly disclosed. The firm is privately held by the Nag family office, employs 1–10 people, and reports no public revenue, AUM, or fee schedule. Go-to-market is deal-by-deal through direct origination, advisor networks anchored by Stanford faculty, and the Institute's event and program pipeline; customer segments are institutional/individual LPs and portfolio founders rather than enterprise SaaS buyers.

R42 Group firmographics

Firmographics
Name
R42 Group
Legal name
R42 Group
Website
https://r42group.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
R42 Group is a Stanford-based private venture capital firm that invents and finances deep-science ventures in AI, biotechnology, and technology through three integrated arms: R42 Ventures (direct and LP investing), R42 Institute (AI and longevity education and community), and the R42 AI Equities Fund (AI-driven public equities).
Ownership category
akta.pro rank

R42 Group industry classification

Industry
Product category
Venture Capital Services
NAICS
Other Financial Vehicles (525990)
akta.pro primary industry
Independent Venture Debt Funds / Platforms (FSANAIAB)
akta.pro secondary industry
Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

  • Venture capital investing
  • Deep science ventures
  • AI startup financing
  • Biotech investment
  • Growth stage capital

Where R42 Group is headquartered

Location

Headquarters

HQ city
Stanford
HQ country
United States
HQ region
North America

Markets served

R42 Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

R42 Group product offering

Product offering

Core offering

R42 Group is a venture capital firm that actively invents and finances deep science ventures across AI, biotechnology, and technology, supporting portfolio companies from pre-seed through growth stage. It operates three integrated arms: R42 Ventures (direct investment and operator support), the R42 Institute (AI and longevity education programs), and the R42 AI Equities Fund (an AI-driven public-markets equity fund).

Product overview

R42 Group operates as a single integrated deep-science platform with three interconnected arms rather than a traditional SaaS product: R42 Ventures finances deep-science startups (AI, biotechnology, technology); the R42 Institute runs the educational and community layer through the R42 AI Fellows Program, R42 AI Founders Institute, R42 AI and Longevity Club, and R42 Longevity Series; and the R42 AI Equities Fund is the firm's AI-driven public-markets investment vehicle that applies predictive analytics and portfolio optimization. Together, these modules form a "invent–invest–inform" stack in which R42 Institute and its events pipeline founders into R42 Ventures' portfolio and inform the AI Equities Fund's strategy, while strategic alliances such as the R42 × capAI PLC partnership extend the platform's AI reach into adjacent media products.

Differentiator

Problem solved

Functional benefit

Brands

  • R42 Ventures: Venture capital arm that invents and finances deep science ventures across AI, biotech, and technology from pre-seed to growth stage
  • R42 Institute
  • R42 AI and Longevity Club
  • R42 AI Equities Fund

Products and services

  • R42 Ventures
  • R42 AI Equities Fund
  • R42 Institute

Companies that use R42 Group

Customer profile

Ideal customer profiles2 records

R42 Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

R42 Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • capAI PLCcoreStrategic or Co-development PartnerR42 has a strategic alliance with capAI PLC.

Recent moves6 records

Expansion highlights5 records

R42 Group competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Deep-tech and science-focused venture capital firm investing in AI, biotech, and frontier technology. Directly comparable to R42's deep-science mandate, with a longer track record and larger fund base, serving similar founders and institutional LPs.
  • Khosla Ventures: Venture capital firm with a strong deep-tech, AI, and biotech investment thesis across pre-seed through growth. Highly comparable to R42 Ventures' thematic scope and stage range, though at significantly larger fund scale.
  • DCVC (Data Collective): Venture capital firm investing in deep-tech companies at the intersection of computation and the physical world (AI, biotech, materials). Directly comparable to R42's deep-science, AI-heavy investment focus.
  • ARCH Venture Partners: Long-standing deep-science and biotech venture capital firm, investing from seed through growth in breakthrough science. Closely matches R42's biotech/longevity and deep-tech emphasis, though typically earlier at the scientific-research stage.
  • Section 32: Venture capital firm investing at the intersection of technology and life sciences (AI, biotech, healthcare). Closely aligned with R42's dual AI/longevity focus and similar stage range from seed to growth.
  • Obvious Ventures: Science-driven venture capital firm investing in AI, health, and sustainable technology. Compares directly to R42's thematic focus on AI and longevity, with overlapping founder and impact-oriented theses.
  • Deep Science Ventures: Venture studio and investor focused on founding deep-science companies across AI, biotech, and climate. Closely mirrors R42's "invent and finance" model of co-creating deep-science ventures from pre-seed, though with a more structured studio approach.
  • AIX Ventures: AI-focused venture capital firm investing in early-stage AI companies, founded by leading AI researchers. Directly comparable to R42 Ventures on the AI investment thesis, with similarly strong research/operator networks and deep-tech specialization.

Broad incumbents

  • Founders Fund: Established broad technology venture capital firm with a deep-tech, science-friendly mandate and AI/tech portfolio exposure. Less specialized in biotech/longevity than R42, but overlapping in AI and frontier-tech investing.

Emerging players

  • Entrepreneur First: Talent-first investor that builds and funds deep-tech founders from the earliest stages. Comparable to R42 Institute's AI Fellows / Founders Institute as a founder-funnel mechanism feeding into R42 Ventures, though EF operates as a global program.

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

R42 Group social profiles

Digital presence

R42 Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

R42 Group leadership team

Management profile

Number of profiles

Profiles13 records

R42 Group subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

R42 Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

R42 Group M&A and investment

M&A and investment

M&A

Investments31 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about R42 Group

What does R42 Group do?

R42 Group is a venture capital firm that actively invents and finances deep science ventures across AI, biotechnology, and technology, supporting portfolio companies from pre-seed through growth stage. It operates three integrated arms: R42 Ventures (direct investment and operator support), the R42 Institute (AI and longevity education programs), and the R42 AI Equities Fund (an AI-driven public-markets equity fund).

Is R42 Group a public or private company?

R42 Group is a private company. It is classified as family owned and is currently operating.

When was R42 Group founded?

R42 Group was founded in 2020. It employs 1 to 10 people.

Where is R42 Group based?

R42 Group is headquartered in Stanford, United States, in the North America region.

Who are R42 Group's main competitors?

Direct peers on record are Lux Capital, Khosla Ventures, DCVC (Data Collective), ARCH Venture Partners, Section 32, Obvious Ventures, Deep Science Ventures and AIX Ventures. Founders Fund is listed as a broad incumbent. Entrepreneur First is listed as an emerging player.

Does R42 Group have an API?

No public API is recorded for R42 Group.

What industry is R42 Group in?

R42 Group's product category is Venture Capital Services. Its primary akta.pro industry code is FSANAIAB, Independent Venture Debt Funds / Platforms, with a secondary code of FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 525990.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvfncapAI PLC Licence and Option Agreement for Ageotype - ADVFNcapAI plc has entered into a licence and option agreement with R42 Group LLC to obtain an exclusive worldwide licence to develop and commercialise Ageotype, an AI-powered longevity and preventative health data platform that integrates multi-modal health data including MRI, blood testing and microbiome analysis. The agreement runs for 12 months and includes an option for capAI to acquire the associated intellectual property for consideration of £2,000,000, with R42 entitled to 20% of net proceeds from future monetisation. The transaction constitutes the company's first platform within its capMedical vertical and represents a material related party transaction as R42 is a venture capital firm founded by Professor Ronjon Nag, Executive Chairman of capAI.Stampfree£1m fundraiseStampfree.ai raised £1.08m in equity investment led by R42, with over 600 investors on Seedrs. The funding will accelerate product development and team scaling. The company aims to expand its AI postal and shipping solutions.Channelxstampfree.ai Raises Over £1 Million to Accelerate Social Returns and AI Innovationstampfree.ai raised £1,029,968 in new investment, with backing from R42 Group and crowdfunding communities. The company launched a WhatsApp-based returns journey and secured EU and US patents for its AI label-free parcel technology. The funding will support product development, international expansion, and further deployment.GlobeNewswirecapAI PLC to Present at the AI & Technology Virtual Investor Conference – Strategic Platform UpdatecapAI PLC announced that its Executive Director Professor Ronjon Nag will present at the AI & Technology Virtual Investor Conference on February 19, 2026. The company highlighted its strategic alliance with R42 Group, its AI media platform capMedia, and its healthcare and longevity initiatives.India Education DiaryUniversity of Exeter: Exeter healthy ageing treatments company raises £2 million in latest seed funding round - India EducationSENISCA, a company spun out of the University of Exeter, has raised £2.15 million in an oversubscribed seed funding round to advance its cell rejuvenation technology for healthy ageing. The investment, led by existing and new investors including R42 Fund and APEX Ventures, will support further laboratory testing and team expansion. The company plans to raise over £5 million in its next seed round scheduled for early 2023.FinSMEsStamp Free Raises £600K in FundingEdinburgh-based digital postage company Stamp Free Limited raised £600,000 in funding led by R42 Group and Cambridge Angels. The company plans to utilize the capital to expand sales and marketing efforts while accelerating product development for its AI-driven digital postage solution.FinSMEsOxford Drug Design Raises £2.2M in Bridge FundingOxford Drug Design raised £2.2 million in bridge funding from investors including ACF Investors, o2h Ventures, and the R42 Group. The company plans to use the capital for cancer drug research, operational expansion, and establishing a new commercial offering of its AI platform. This brings the firm's total funding to over £10 million ahead of an anticipated Series A round.